Annovis Bio to Present Buntanetap Data at CTAD, Signaling Progress Toward 2027 Pivotal Readout

Annovis Bio's three presentations at the 2026 CTAD conference will showcase buntanetap's mechanism, Phase 3 trial design, and AI-driven blood-brain barrier prediction, underscoring the company's momentum ahead of a pivotal data readout and planned New Drug Application.

Chicago Metrowire Staff
••Healthcare
Annovis Bio to Present Buntanetap Data at CTAD, Signaling Progress Toward 2027 Pivotal Readout

Annovis Bio (NYSE: ANVS) will deliver three presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston, the company announced. The presentations will cover the investigational oral therapy buntanetap, including its mechanism of action targeting neurotoxic proteins, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer's disease, and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer's drug candidates. The program features an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, and two poster presentations on Nov. 16-17, including one by Chief Scientific Officer Cheng Fang.

The importance of these presentations lies in their timing: they come as Annovis approaches a pivotal clinical data readout in early 2027 and prepares for a New Drug Application. For investors and the broader Alzheimer's research community, the CTAD platform offers a critical opportunity to scrutinize the science behind buntanetap before the definitive Phase 3 results. The inclusion of an AI-driven permeability model also signals the company's broader interest in leveraging advanced tools to de-risk drug development.

Buntanetap is a once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions. The company is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology firm developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.

For investors, the latest news and updates relating to ANVS are available in the company's newsroom at https://nnw.fm/ANVS. The full press release can be viewed at https://nnw.fm/2k4SQ. The announcement was distributed by NetworkNewsWire, a specialized communications platform and one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services.

Blockchain Registration

QR Code for Blockchain Registration